Yep, I agree! Unlike a lot of other bio's with multiple competitors in their space and current treatment options, Neuren really has a first mover advantage in this space too. Very exciting!
All I am saying is that I'm not so sure the market is going to realise all that (or be willing to bet on it) off the results alone, even if they are clinically excellent. Maybe some years ago it would be enough, but I think in this present time the deals need to be well advanced. Just my interpretation and trying to keep my expectations in check so not to be disappointed if it doesn't fly. Hoping for the best for all of us holders and of course the patients suffering with these disorders.
Yep, I agree! Unlike a lot of other bio's with multiple...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |